Calculating global risk: The key to intervention

European Heart Journal, Supplement

Volumn 7, Issue F, 2005, Pages

  Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cardiovascular risk; Cardiovascular risk engines; Coronary heart disease

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ALGORITHM; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FAMILY HISTORY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MATHEMATICAL MODEL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WORLD HEALTH ORGANIZATION;

EID: 32044468106     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui037     Document Type: Conference Paper

References (29)

1. Prevention of coronary heart disease in clinical practice: recommendations of the second joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434-1503.
2. Kannel WB, Cupples LA, D'Agostino RB et al. Hypertension, antihypertensive treatment, and sudden coronary death. The Framingham Study. Hypertension 1988;11:II45-II50.
3. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
4. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H-9H.
5. Kannel WB, Dawber TR, Friedman GD et al. Risk factors in coronary heart disease. an evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann Intern Med 1964;61:888-899.
6. Doyle JT, Dawber TR, Kannel WB et al. The relationship of cigarette smoking to coronary heart disease; the second report of the combined experience of the Albany, NY, and Framingham, Mass, studies. JAMA 1964;190:886-890.
7. De Backer G, Ambrosini E, Borch-Johnsen K. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.
8. National Cholesterol Education Program. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health/National Heart Lung and Blood Institute, www.nhlbi.nih.gov/guidelines/cholesterol
9. Framingham risk calculator. http://hin.nhlbi.nih.gov/atpiii/calculator. asp (December 2004).
10. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-315.
11. Assmann G, Schulte H, Cullen P. New and classical risk factors - the Munster heart study (PROCAM). Eur J Med Res 1997;2:237-242.
12. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-737.
13. von Eckardstein A, Schulte H, Cullen P et al. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001;37:434-439.
14. Sandkamp M, Funke H, Schulte H et al. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990;36:20-23.
15. Berger K, Schulte H, Stogbauer F et al. Incidence and risk factors for stroke in an occupational cohort: the PROCAM Study. Prospective Cardiovascular Munster Study. Stroke 1998;29:1562-1566.
16. Jaross W, Assmann G, Bergmann S et al. Comparison of risk factors for coronary heart disease in Dresden and Munster. Results of the DRECAN (Dresden Cardiovascular Risk and Nutrition) study and the PROCAM (Prospective Cardiovascular Munster) Study. Eur J Epidemiol 1994;10:307-315.
17. Assmann G, Cullen P, Heinrich J et al. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996;32:364-370.
18. Heinrich J, Balleisen L, Schulte H et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-59.
19. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116:1713-1724.
20. Hense HW, Schulte H, Lowel H et al. Framingham risk function over-estimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937-945.
21. PROCAM risk calculator. http://chdrisk.uni-muenster.de/calculator.php (December 2004).
22. Assmann G, Schulte H, von Eckardstein A et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl.):S11-S20.
23. UK Prospective Diabetes Study risk calculator. http://www.dtu.ox.ac.uk/ riskengine (December 2004).
24. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714.
25. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-113.
26. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28:83-87.
27. Assmann G, Schulte H. Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study. Drugs 1990;40(Suppl. 1):13-18.
28. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
29. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651.